Abstract: This invention provides a composition comprising a first compound selected from Formula 1, an N-oxide or an agriculturally suitable salt thereof; and a second compound selected from neonicotinoids, wherein R1, R2, R3, R4a, R4b and R5 are as defined in the disclosure.
Type:
Grant
Filed:
December 26, 2012
Date of Patent:
May 12, 2015
Assignee:
E I du Pont de Nemours and Company
Inventors:
George Philip Lahm, Thomas Paul Selby, Thomas Martin Stevenson
Abstract: This invention relates to the design, synthesis and use of synthetic vitamin D and other steroidal analogs. It further relates to the therapeutic use of such analogs and their manufacture.
Type:
Grant
Filed:
December 12, 2006
Date of Patent:
May 5, 2015
Assignee:
Women & Infants' Hospital of Rhode Island
Abstract: The invention relates to a process for the preparation of a compound of formula (I): wherein R1 and R2 are as defined in the description, by reaction of a compound of formula (II) with a base. Compound (I) is an intermediate useful in the preparation of gestodene.
Abstract: The present invention pertains to tetracycline compounds of formula (VIIa): R5*, R5*?, R7r*, and R9m* are defined herein. These tetracycline compounds can be used to treat tetracycline compound-responsive states, such as multiple sclerosis and rheumatoid arthritis.
Abstract: To provide a novel vitamin D3 derivative useful as a therapeutic agent for osteoporosis. Provided is a vitamin D3 derivative represented by the following formula (1) or a medicinally acceptable solvate thereof: wherein R1 represents a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, an alkylcarbonyloxyalkyl group with each alkyl having 1 to 6 carbon atoms, or an arylcarbonyloxyalkyl group with the aryl having 6 to 10 carbon atoms and the alkyl having 1 to 6 carbon atoms; R2 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms or, together with the other R2 and the carbon atom to which they are bound to, may form a cyclic alkyl group having 3 to 6 carbon atoms; R3 represents an alkyl group having 1 to 6 carbon atoms or, together with the other R3 and the carbon atom to which they are bound to, may form a cyclic alkyl group having 3 to 6 carbon atoms; X represents an oxygen atom or a methylene group; and n represents an integer of 1 or 2.
Abstract: The invention is directed to thiophenecarboxamide derivatives of formulae I and II as EP4 receptor ligands, antagonists or agonists, useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis, cancer and glaucoma. Pharmaceutical compositions and methods of use are also included. (Formulas I and II).
Type:
Grant
Filed:
August 10, 2007
Date of Patent:
March 3, 2015
Assignee:
Merck Frosst Canada Ltd.
Inventors:
Marc Blouin, Jason Burch, Yongxin Han, Christophe Mellon
Abstract: Formula (I) and (II). The present invention relates to the use of a new lupane derivative of general formula (I) or (II), or a pharmaceutically acceptable salt, crystal form, complex, hydrate, or hydrolysable ester thereof, for preventing and/or inhibiting tumor growth and for treating cancer and other proliferative diseases, more particularly for treating leukemia, liver, cervical, colon and prostate cancer. The present invention also relates to the synthesis of these compounds and to pharmaceutical compositions which contain them.
Type:
Grant
Filed:
May 20, 2010
Date of Patent:
March 3, 2015
Assignee:
Universidade de Coimbra
Inventors:
Jorge Antonio Ribeiro Salvador, Rita Catarina Mendes Dos Santos, Marta Cascante Serratosa
Abstract: Disclosed are methods of purifying the compound (20R)-2-methylene-19-nor-24-difluoro-1?,25-dihydroxyvitamin D3 to obtain the compound in crystalline form. The methods typically include the steps of dissolving a product containing the compound in a solvent comprising hexane and 2-propanol, cooling the solvent and dissolved product below ambient temperature for a sufficient amount of time to form a precipitate of crystals, and recovering the crystals.
Type:
Grant
Filed:
March 14, 2013
Date of Patent:
January 27, 2015
Assignee:
Wisconsin Alumni Research Foundation
Inventors:
Hector F. DeLuca, Agnieszka Flores, James B. Thoden, Hazel M. Holden
Abstract: Compounds of formula (1) wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is 2-methyl-1,3-oxazol-4-yl and R4 and R5 together with the nitrogen atom to which they are attached represents morpholino, process for their preparation, pharmaceutical compositions containing them and their use in medicine.
Abstract: The present invention relates to processes for the crystallisation and for the preparation and isolation of a novel crystalline form of fusidic acid, to the use of said processes in the manufacture of pharmaceutical formulation or medicament, and to the use of said crystalline fusidic acid form for the treatment of bacterial infections.
Abstract: The invention relates to nitrooxyderivative of corticosteroids of general formula (I) and pharmaceutically acceptable salts or stereoisomers thereof R—(Z)a—Rx??(I) wherein R is the corticosteroid residue of formula (II): wherein: R1 is OH, R2—CH3, or R1 and R2 are taken together to form a group of formula (III) R3 is Cl or F; R4 is H or F; wherein R1, R2, R3 and R4 can be linked to the correspondent carbon atoms of the steroidal structure in position ? or ?; with the proviso that: when R1 and R2 are the group of formula (III) then R3 is F and R4 is H or F; The compounds are useful in the treatment of respiratory diseases, inflammatory diseases, dermatological diseases and ocular diseases.
Abstract: This invention provides a composition comprising a biologically effective amount of a compound of Formula 1, an N-oxide or an agriculturally suitable salt thereof wherein R1, R2, R3, R4a, R4b and R5 are as defined in the disclosure, and an effective amount of at least one fungicide.
Type:
Grant
Filed:
March 6, 2012
Date of Patent:
December 30, 2014
Assignee:
E I du Pont de Nemours and Company
Inventors:
George Philip Lahm, Thomas Paul Selby, Thomas Martin Stevenson
Abstract: The present invention provides novel 16,23-diene 25-oxime ether analogs of 1,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the novel compound of the invention are useful for treating diseases which benefit from a modulation of the levels of 1,25-dihydroxy vitamin D3, for example, cell-proliferative disorders.
Type:
Grant
Filed:
April 25, 2006
Date of Patent:
December 9, 2014
Assignees:
Cytochroma Inc., Johns Hopkins University
Inventors:
Uttam Saha, Gary H. Posner, Mehmet Kahraman
Abstract: Disclosed are methods of purifying (20R) and (20S) analogs of 2-methylene-19-nor-22-dimethyl-1?,25-dihydroxyvitamin D3 to obtain the (20R) and (20S) analogs in crystalline form. The method includes the steps of preparing a solvent of either diethyl ether or a mixture of 2-propanol and hexane, dissolving a product containing the (20R) and (20S) analog to be purified in the solvent, cooling the solvent and dissolved product below ambient temperature for a sufficient amount of time to form a precipitate of crystals, and recovering the crystals.
Type:
Grant
Filed:
March 14, 2013
Date of Patent:
November 11, 2014
Assignee:
Wisconsin Alumni Research Foundation
Inventors:
Hector F. DeLuca, Agnieszka Flores, James B. Thoden, Hazel M. Holden
Abstract: The present invention relates to a process for the preparation of 17?-(3-hydroxypropyl)-17?-hydroxysteroids of the formula I starting from 17-ketosteroids of the formula III via the intermediates of the formula V wherein the radicals R3, R5, R6, R7, R10, R13, R15, R16, R40, R41 and R42 have the meaning indicated in the description.
Type:
Grant
Filed:
June 27, 2008
Date of Patent:
October 7, 2014
Assignee:
Bayer Intellectual Property GmbH
Inventors:
Claus Christian Haeselhoff, Mike Petersen
Abstract: Bromoacetoxycalcidiol (B3CD), which is structurally related to calcidiol, exhibits cytotoxic and apoptotic activity toward cancer cells, including highly aggressive neuroblastoma cells. A series of small molecules designed around the structure of B3CD is expected to have growth inhibitory and apoptogenic activities toward a wide range of malignancies. B3CD shows no apparent toxicity in vivo, indicating potential value as a chemotherapeutic agent which will be particularly useful in treating highly aggressive tumors.
Abstract: The invention concerns the production of quinoline compounds containing sulfonic acid groups, the said quinoline compounds and their conversion into dyes containing sulfonic acid groups. The dyes according to the invention are used especially to label analytes, for example to label biomolecules.
Abstract: A method of forming an azido energetic alcohol includes converting an energetic diol to a cyclic sulfite, oxidizing the cyclic sulfite to a cyclic sulfate, and opening the cyclic sulfate. The cyclic sulfate is opened, followed by hydrolysis, to form an azido energetic alcohol.
Type:
Grant
Filed:
June 23, 2010
Date of Patent:
September 23, 2014
Assignee:
Physical Sciences, Inc.
Inventors:
Alicia Thompson, Ana Racoveanu, David Skyler